Brachytherapy for targeting the immune system in cervical cancer patients

BMC Immunology

Table 4 Difference of MDSCs subpopulation percentages between baseline and after completion of CRT and two and four weeks after completion HDR and PDR Brachytherapy

	Baseline vs. Treatment Friedman Test	CT-RT vs. Baseline Conover Test	2w BT vs. Baseline Conover Test	4w BT vs. Baseline Conover Test	2w BT vs. End CT-RT Conover Test	4w BT vs. End CT-RT Conover Test	2w vs. 4w after BT Conover Test
	p	p	p	p	p	p	p
*HDR*
MDSC (CD33⁺CD11b⁺)	< 0.0051	< 0.0032	< 3.6E^-05	< 0.0021	< 0.0274	< 0.7152	< 0.0470
G-CD33⁺CD11b⁺CD14⁻	< 0.0997	< 0.1074	< 0.1891	1	< 0.0140	< 0.1074	< 0.1891
Mo-CD33⁺CD11b⁺CD14^{+ HLADR−/low}	< 0.0737	< 0.0120	< 0.0991	< 0.3788	< 0.2249	< 0.0433	< 0.2934
*PDR*
MDSC (CD33⁺ CD11b⁺)	< 7.8E^-06	< 1.0E-12	< 1.0E^-12	< 3.0E^-07	1	< 2.3E^-05	< 2.3E^-05
G-CD33⁺CD11b⁺CD14^-	< 0.4580	< 0.8928	< 0.7090	< 0.1323	< 0.7090	< 0.1323	< 0.0874
Mo-CD33⁺CD11b⁺CD14^{+ HLADR−/low}	< 0.2100	< 0.0057	< 0.0648	< 0.2065	< 0.2065	< 0.0648	< 0.4083

ISSN: 1471-2172